Aethon’s HapImmune™ platform, described in a recent publication in the journal Cancer Discovery, unites immunotherapy and targeted therapy
$30M in Series A funding, with $25M from Apple Tree Partners (ATP) and participation by NYU Langone Health
NEW YORK, January 9, 2023 – New therapies targeting oncogenic mutations in proteins such as RAS and EGFR hold great promise for people fighting cancer. However, their efficacy is limited by tumor cells’ ability to develop resistance to these drugs, which can lead to disease recurrence.
Today, Aethon Therapeutics launches to create novel antibodies designed to eliminate drug resistance by enabling the immune system to find and kill persistent cancer cells. Apple Tree Partners (ATP), a leader in life sciences venture capital, co-founded Aethon with researchers from NYU Langone Health’s Perlmutter Cancer Center – Shohei Koide, Ph.D. and Benjamin G. Neel, M.D., Ph.D. – inventors of the HapImmune™ immunotherapy platform that is Aethon’s drug discovery engine. Aethon is funded with $30 million in Series A financing, $25 million of which comes from ATP. NYU Langone Health also participated in this funding round and holds equity in Aethon.
Raj Chopra, FRCP, FRCPath, FRSB, Ph.D., Head of Oncology for ATP, and a Venture Partner at the firm, is acting Chief Executive Officer for Aethon, and Paul Da Silva Jardine, Ph.D., an ATP Venture Partner, is acting Chief Scientific Officer for the new company, which is based in New York City. Seth Harrison, M.D., ATP founder and managing partner, chairs Aethon’s Board of Directors. Drs. Koide and Neel are scientific advisors to Aethon.
“ATP worked with Drs. Koide and Neel to establish Aethon because we were struck by the novelty of their original observation: That when covalent inhibitors bind to their target proteins inside cancer cells, they produce a peptide conjugate ‘beacon’ that is delivered only to the surface of cancer cells, not to healthy cells. Aethon has discovered customized antibodies that home in on that beacon, making the cancer cells vulnerable to attack,” Dr. Chopra said. “Aethon is moving quickly to advance programs focused on combinations with KRAS and EGFR inhibitors, and over the mid to long term we plan to develop other bespoke drug-antibody combinations.”
Aethon’s proprietary HapImmune™ platform is a mechanism to increase the antigenicity of any cancer-specific protein that can be targeted with any covalent drug and presented by the major histocompatibility complex (MHC), an essential component of the adaptive immune system. The antibodies produced via the HapImmune platform are designed to activate T cells that will specifically kill tumor cells. HapImmune uses NYU Langone Health’s proprietary repertoire of 100 billion synthetic antibody sequences to find antibodies that recognize drug-peptide complexes (haptens) presented by MHC molecules while avoiding binding to wild-type (e.g., drug-free) peptides on the same MHCs or to the free drug.
The chosen antibodies are then reformatted into custom bi-specific T cell engagers, with one recognition arm directed toward the drug-peptide:MHC and the other toward T cell surface proteins, to recruit T cells to attack the tumor cells. In vitro studies have shown that such engineered antibodies can selectively kill drug-treated resistant tumor cells. The HapImmune platform is described in an article published online recently in Cancer Discovery, a journal of the American Association for Cancer Research.
“Immuno-oncology therapy can be curative, but it is not applicable to most tumors or intracellular proteins because many cancers lack neo-antigens recognizable by the immune system,” said Dr. Koide. “We are excited to be part of new efforts in the field to improve and extend the effects of targeted therapy and prevent resistance and relapse. By uniting immunotherapy and targeted therapy in this way, we hope to amplify the power of both.”
“This is an amazing opportunity, and we are grateful to everyone who has been a part of this research over the years,” Dr. Neel said. “’We are excited to deploy the HapImmune platform to advance new therapeutic approaches that we believe will ultimately help many people to not only fight cancer—but to fight cancer and win.”
NYU Langone Health and its Technology Opportunities & Ventures arm has exclusively licensed to Aethon pending patent applications and expertise covering the HapImmune™ platform. NYU Langone Health is the owner of the technology exclusively licensed to Aethon and has equity and other financial interests in Aethon. Drs. Koide and Neel also have equity in Aethon, and Aethon is also sponsoring research conducted by Dr. Koide and Dr. Neel at NYU Langone Health. These interests are being disclosed and managed in accordance with NYU Langone Health policies.
 T. Hattori T, Maso L, Araki K, Koide A, Hayman J, Akkapedi P, Bang I, Neel B, Koide S. Creating MHC-Restricted Neoantigens with Covalent Inhibitors That Can Be Targeted by Immune Therapy. Cancer Discovery, January 2023 print edition, first published October 2022. https://aacrjournals.org/cancerdiscovery/article/doi/10.1158/2159-8290.CD-22-1074/711560/Creating-MHC-Restricted-Neoantigens-with-Covalent. Accessed on January 7, 2023.
About Aethon Therapeutics
Aethon Therapeutics, an ATP company, creates neoantigens by design, to transform cancer treatments into cures. Aethon’s novel anti-drug-peptide conjugate/MHC antibodies, engineered using the company’s proprietary HapImmune™ platform, are designed to be used in combination with targeted covalent inhibitors (TCI) of RAS, EGFR, and other oncogenic driver mutations, to mount immune attacks to selectively kill residual cancer cells, including drug-resistant “persister” cells. Aethon unites immunotherapy and targeted therapy to expand the power and promise of both approaches for people living with cancer. For more information, visit www.aethontx.com.
Founded in 1999, ATP is a leader in life sciences venture capital, with $2.65 billion in committed capital and offices in New York, London, San Francisco, and Cambridge, MA. ATP creates companies starting at various stages, from pre-IP ideas to asset spinouts, investing in them from seed stage through IPO and beyond. The core of ATP’s strategy is providing flexible capital and access to a world-class team of venture partners and EIRs, to build sustainable, research-driven enterprises that deliver therapeutics to improve human lives. For more information, visit www.appletreepartners.com.
Sally Jacob, ATP